Dotmatics Introduces Luma Antibody & Protein Engineering Solution for End-to-End Antibody Discovery
The first in a series of Dotmatics Luma Multimodal R&D Solutions Geneious has been seamlessly composed into Luma showcasing cross-therapeutic...
Vaccine
PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine
Study to evaluate PDS01ADC + Xtandi® (Enzalutamide) versus Xtandi® alone to be presented by Dr. Ravi Madan, National Cancer Institute...
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184
Company to conduct a Phase 1 Drug-Drug Interaction StudyPhase 2 filing on track for Q1 2025 SOUTH SAN FRANCISCO, Calif.,...
Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease
Determined the high dose of OCU410ST to be the maximum tolerated doseNo serious adverse events have been reportedApproved proceeding to...
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults...
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults...
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults...
Bioprocessing Market Size Worth $72.55 Billion, Globally, by 2031 – Exclusive Report by The Insight Partners
The Bioprocessing Market share is expected to reach US$ 72.55 billion by 2031 from US$ 25.35 billion in 2023 to record...
Global Health Exhibition Launches in Riyadh, Witnessing SAR 50 Billion in Investments on its First Day
RIYADH, Saudi Arabia, Oct. 21, 2024 /PRNewswire/ -- The seventh edition of the Global Health Exhibition has kicked off under the...
Global Health Exhibition Opens its Doors Tomorrow to Record-Breaking 100,000+ Attendees to World’s Premier Healthcare Transformation Event
Kingdom of Saudi Arabia opens the Global Health Exhibition (21-23 October 2024) tomorrow, a major international healthcare event with 100,000+...
Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
CAMBRIDGE, MA / ACCESSWIRE / October 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live...
Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
CAMBRIDGE, MA / ACCESSWIRE / October 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live...
Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq
PRINCETON, NJ, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage...
Sarah Sheikh Joins Cerevance’s Board of Directors
BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment...
Tonix Pharmaceuticals Receives First Contract Payment from U.S. Department of Defense for Accelerated Development of Broad-Spectrum Antivirals with the Defense Threat Reduction Agency (DTRA)
First payment received under Tonix’s contract with the Defense Threat Reduction Agency (DTRA), for up to $34 million over five...
Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results
MALVERN, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused...
Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024
ATI-1701 provides full protection against lethal tularemia in animal models after one year Company to provide update on tularemia vaccine...
Sanofi commits $18 million to Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine to increase diversity in clinical studies
BRIDGEWATER, N.J., Oct. 16, 2024 /PRNewswire/ -- Sanofi announced today it will contribute $18 million to three Historically Black Medical...
Fencing Equipment Market to Grow by USD 61.7 Million (2024-2028) as Combat Sports Gain Popularity, with AI Redefining the Market Landscape- Technavio
NEW YORK, Oct. 15, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The Global Fencing Equipment Market...
Medicare Open Enrollment Runs Through Dec. 7
Reviewing your Medicare options could save you money MISSION, Kan., Oct. 15, 2024 /PRNewswire/ -- (Family Features) If you're enrolled...